Notice ID: 4ba05de659e943e68637a92f7c01b262Combined Synopsis/Solicitation
Vaccine Adverse Event Reporting System (VAERS) and Safety Monitoring Support for COVID-19 Vaccines
Archived on April 26, 2023. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 4:30 PM UTC−04:00
- Posted
- May 2, 2023
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- 8(a) Set-Aside (FAR 19.8)
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION
Notice details
- Office
- FDA OFFICE OF ACQ GRANT SVCS
- Last updated
- Sep 9, 2025
Identifiers
- Solicitation number
- FDA-RFP-116785
- Notice ID
- 4ba05de659e943e68637a92f7c01b262
Description
This project will fund a senior physician with Vaccine Adverse Event Reporting Subject Matter expertise to work on adverse neurological and other events associated with COVID-19 vaccinations. Currently there are two FDA-approved COVID-19 vaccines: Comirnaty (COVID-19 Vaccine, mRNA) Pikevax (COVID-19 Vaccine, mRNA) See attached solicitation for more information. There are four COVID-19 vaccines authorized for emergency use in the U.S.: Janssen (J&J) COVID-19 Vaccine Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine, Bivalent Novavax COVID-19 Vaccine, Adjuvanted Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent As with all vaccines and other medical products, although the vaccine development process and FDAs evaluation are rigorous and comprehensive, after a vaccine for COVID-19 is authorized under EUA by FDA, or following licensure (approval) of a BLA, additional pharmacovigilance will be conducted to monitor COVID-19 vaccine safety and effectiveness. Additionally, the senior physician will be tasked with various projects identified by OBPV/DPV to fulfill statutory obligations, user fee commitments, specific Center or Agency goals.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
FDA-RFP-116785- Combined Synopsis
- 2×Combined SynopsisCurrentApr 18, 2023
Vaccine Adverse Event Reporting System (VAERS) and Safety Monitoring Support for COVID-19 Vaccines
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
FDA-RFP-116785
Archive Date
Apr 26, 2023
Office Address
Beltsville, MD, 20705